Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 49

1.

ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time.

Gerber DE, Minna JD.

Cancer Cell. 2010 Dec 14;18(6):548-51. doi: 10.1016/j.ccr.2010.11.033. Review.

2.

Suppression of Rev3, the catalytic subunit of Pol{zeta}, sensitizes drug-resistant lung tumors to chemotherapy.

Doles J, Oliver TG, Cameron ER, Hsu G, Jacks T, Walker GC, Hemann MT.

Proc Natl Acad Sci U S A. 2010 Nov 30;107(48):20786-91. doi: 10.1073/pnas.1011409107. Epub 2010 Nov 10.

3.

Diverse somatic mutation patterns and pathway alterations in human cancers.

Kan Z, Jaiswal BS, Stinson J, Janakiraman V, Bhatt D, Stern HM, Yue P, Haverty PM, Bourgon R, Zheng J, Moorhead M, Chaudhuri S, Tomsho LP, Peters BA, Pujara K, Cordes S, Davis DP, Carlton VE, Yuan W, Li L, Wang W, Eigenbrot C, Kaminker JS, Eberhard DA, Waring P, Schuster SC, Modrusan Z, Zhang Z, Stokoe D, de Sauvage FJ, Faham M, Seshagiri S.

Nature. 2010 Aug 12;466(7308):869-73. doi: 10.1038/nature09208. Epub 2010 Jul 28.

PMID:
20668451
4.

Requirement of the NF-kappaB subunit p65/RelA for K-Ras-induced lung tumorigenesis.

Bassères DS, Ebbs A, Levantini E, Baldwin AS.

Cancer Res. 2010 May 1;70(9):3537-46. doi: 10.1158/0008-5472.CAN-09-4290. Epub 2010 Apr 20.

5.

Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer.

Oliver TG, Mercer KL, Sayles LC, Burke JR, Mendus D, Lovejoy KS, Cheng MH, Subramanian A, Mu D, Powers S, Crowley D, Bronson RT, Whittaker CA, Bhutkar A, Lippard SJ, Golub T, Thomale J, Jacks T, Sweet-Cordero EA.

Genes Dev. 2010 Apr 15;24(8):837-52. doi: 10.1101/gad.1897010.

6.

Knockout of the tumor suppressor gene Gprc5a in mice leads to NF-kappaB activation in airway epithelium and promotes lung inflammation and tumorigenesis.

Deng J, Fujimoto J, Ye XF, Men TY, Van Pelt CS, Chen YL, Lin XF, Kadara H, Tao Q, Lotan D, Lotan R.

Cancer Prev Res (Phila). 2010 Apr;3(4):424-37. doi: 10.1158/1940-6207.CAPR-10-0032. Epub 2010 Mar 30.

7.

Imaging primary lung cancers in mice to study radiation biology.

Kirsch DG, Grimm J, Guimaraes AR, Wojtkiewicz GR, Perez BA, Santiago PM, Anthony NK, Forbes T, Doppke K, Weissleder R, Jacks T.

Int J Radiat Oncol Biol Phys. 2010 Mar 15;76(4):973-7. doi: 10.1016/j.ijrobp.2009.11.038.

8.

Discovering NF-kappaB.

Baltimore D.

Cold Spring Harb Perspect Biol. 2009 Jul;1(1):a000026. doi: 10.1101/cshperspect.a000026.

9.

Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1.

Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, Schinzel AC, Sandy P, Meylan E, Scholl C, Fröhling S, Chan EM, Sos ML, Michel K, Mermel C, Silver SJ, Weir BA, Reiling JH, Sheng Q, Gupta PB, Wadlow RC, Le H, Hoersch S, Wittner BS, Ramaswamy S, Livingston DM, Sabatini DM, Meyerson M, Thomas RK, Lander ES, Mesirov JP, Root DE, Gilliland DG, Jacks T, Hahn WC.

Nature. 2009 Nov 5;462(7269):108-12. doi: 10.1038/nature08460. Epub 2009 Oct 21.

10.

Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma.

Meylan E, Dooley AL, Feldser DM, Shen L, Turk E, Ouyang C, Jacks T.

Nature. 2009 Nov 5;462(7269):104-7. doi: 10.1038/nature08462. Epub 2009 Oct 21.

11.

Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase.

DuPage M, Dooley AL, Jacks T.

Nat Protoc. 2009;4(7):1064-72. doi: 10.1038/nprot.2009.95. Epub 2009 Jun 25.

12.

Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma.

Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, Shen Q, Bertoni F, Ponzoni M, Scandurra M, Califano A, Bhagat G, Chadburn A, Dalla-Favera R, Pasqualucci L.

Nature. 2009 Jun 4;459(7247):717-21. doi: 10.1038/nature07968. Epub 2009 May 3.

13.

Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls.

Baud V, Karin M.

Nat Rev Drug Discov. 2009 Jan;8(1):33-40. doi: 10.1038/nrd2781. Review.

14.

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.

Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, Maira M, McNamara K, Perera SA, Song Y, Chirieac LR, Kaur R, Lightbown A, Simendinger J, Li T, Padera RF, García-Echeverría C, Weissleder R, Mahmood U, Cantley LC, Wong KK.

Nat Med. 2008 Dec;14(12):1351-6. doi: 10.1038/nm.1890. Epub 2008 Nov 30.

15.

An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer.

Zender L, Xue W, Zuber J, Semighini CP, Krasnitz A, Ma B, Zender P, Kubicka S, Luk JM, Schirmacher P, McCombie WR, Wigler M, Hicks J, Hannon GJ, Powers S, Lowe SW.

Cell. 2008 Nov 28;135(5):852-64. doi: 10.1016/j.cell.2008.09.061. Epub 2008 Nov 13.

16.

Lung cancer.

Herbst RS, Heymach JV, Lippman SM.

N Engl J Med. 2008 Sep 25;359(13):1367-80. doi: 10.1056/NEJMra0802714. Review. No abstract available.

PMID:
18815398
17.

Many facets of bortezomib resistance/susceptibility.

Kumar S, Rajkumar SV.

Blood. 2008 Sep 15;112(6):2177-8. doi: 10.1182/blood-2008-07-167767. No abstract available.

18.

Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein.

Oerlemans R, Franke NE, Assaraf YG, Cloos J, van Zantwijk I, Berkers CR, Scheffer GL, Debipersad K, Vojtekova K, Lemos C, van der Heijden JW, Ylstra B, Peters GJ, Kaspers GL, Dijkmans BA, Scheper RJ, Jansen G.

Blood. 2008 Sep 15;112(6):2489-99. doi: 10.1182/blood-2007-08-104950. Epub 2008 Jun 18.

19.

DLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma.

Xue W, Krasnitz A, Lucito R, Sordella R, Vanaelst L, Cordon-Cardo C, Singer S, Kuehnel F, Wigler M, Powers S, Zender L, Lowe SW.

Genes Dev. 2008 Jun 1;22(11):1439-44. doi: 10.1101/gad.1672608.

20.

IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis.

Vince JE, Wong WW, Khan N, Feltham R, Chau D, Ahmed AU, Benetatos CA, Chunduru SK, Condon SM, McKinlay M, Brink R, Leverkus M, Tergaonkar V, Schneider P, Callus BA, Koentgen F, Vaux DL, Silke J.

Cell. 2007 Nov 16;131(4):682-93.

Supplemental Content

Support Center